$6.31
0.274.47%
At close: Jul 15, 5:00 PM EST
$6.32
0.010.16%
After Hours: 4:15 PM EST
Myriad Genetics Inc Stock Guidance
MYGNNASDAQ
Myriad Genetics (MYGN) last issued guidance on May 5, 2026 for fiscal year 2026. The company guided revenue in the range of $860.00M - $880.00M for the period.
Compared to prior guidance, Myriad Genetics maintained its revenue forecast from a prior range of $860.00M - $880.00M.
Myriad Genetics has issued 28 guidance updates between August 4, 2022 and May 5, 2026. During this period, the company raised its outlook 7 times and lowered it 8 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
May 5, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$860.00M - $880.00M
Myriad Genetics Guidance History
Review all historical guidance issued by Myriad Genetics, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Myriad Genetics (MYGN)?
The most recent guidance for Myriad Genetics (MYGN) was reported on May 5, 2026 for the fiscal year 2026. Myriad Genetics forecasted revenue between $860.00M and $880.00M for the period.
What EPS range did Myriad Genetics (MYGN) guide for?
Myriad Genetics (MYGN) guided EPS in the range of $-0.02 to $0.02 for the fiscal year 2025. The consensus analyst EPS estimate is $-0.16.
What revenue range did Myriad Genetics (MYGN) guide for?
Myriad Genetics (MYGN) guided revenue in the range of $860.00M to $880.00M for the fiscal year 2026.
Did Myriad Genetics (MYGN) raise or lower guidance?
Myriad Genetics (MYGN) maintained its revenue guidance from a prior range of $860.00M - $880.00M to $860.00M - $880.00M for the fiscal year 2026.
When did Myriad Genetics (MYGN) last issue guidance?
Myriad Genetics (MYGN) last issued guidance on May 5, 2026 for the fiscal year 2026.
